v3.23.2
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2022
Feb. 28, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K/A    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-36352    
Entity Registrant Name AKEBIA THERAPEUTICS, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 20-8756903    
Entity Address, Address Line One 245 First Street    
Entity Address, City or Town Cambridge    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02142    
City Area Code 617    
Local Phone Number 871-2098    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Trading Symbol AKBA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 64,134,957
Entity Common Stock, Shares Outstanding   184,248,045  
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001517022    
Amendment Flag true    
Amendment Description This Amendment No. 1 is being filed to revise the Company's consolidated financial statements previously filed by the Company with the SEC for each of the fiscal years ended December 31, 2022, 2021 and 2020 as a result of certain accounting errors relating to the completeness, accuracy and disclosure of reserves for product returns and to update the Company's assessment of its internal control over financial reporting and its disclosure controls and procedures because of a material weakness identified by the Company to indicate that they were not effective as of December 31, 2022.